Pain And Itch Relief
Daphne Mezereum Bark, Gelsemium Sempervirens Root
Magni Group
Human Otc Drug
NDC 43689-0029Pain And Itch Relief also known as Daphne Mezereum Bark, Gelsemium Sempervirens Root is a human otc drug labeled by 'Magni Group'. National Drug Code (NDC) number for Pain And Itch Relief is 43689-0029. This drug is available in dosage form of Gel. The names of the active, medicinal ingredients in Pain And Itch Relief drug includes Daphne Mezereum Bark - 6 [hp_X]/51g Gelsemium Sempervirens Root - 6 [hp_X]/51g . The currest status of Pain And Itch Relief drug is Active.
Drug Information:
| Drug NDC: | 43689-0029 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Pain And Itch Relief |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Daphne Mezereum Bark, Gelsemium Sempervirens Root |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Magni Group |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Gel |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | DAPHNE MEZEREUM BARK - 6 [hp_X]/51g
GELSEMIUM SEMPERVIRENS ROOT - 6 [hp_X]/51g
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 06 Jul, 2017 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 09 May, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Magni Group
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UPC: | 0723122150230
|
| UPC stands for Universal Product Code. |
| UNII: | X2N6E405GV
639KR60Q1Q
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 43689-0029-1 | 1 JAR in 1 BOX (43689-0029-1) / 51 g in 1 JAR | 06 Jul, 2017 | N/A | No |
| 43689-0029-2 | 51 g in 1 JAR (43689-0029-2) | 06 Jul, 2017 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose anti-itch external analgesic
Product Elements:
Pain and itch relief daphne mezereum bark, gelsemium sempervirens root alcohol aloe vera leaf ascorbic acid citrus aurantium flower c13-14 isoparaffin caramel carbomer 940 chamaemelum nobile flower echinacea angustifolia lavender oil glycerin laureth-7 lysine phenylpropanol piperonal potassium sorbate ppg-2 methyl ether propylene glycol sage sodium benzoate .alpha.-tocopherol acetate trolamine water methyl salicylate witch hazel achillea millefolium daphne mezereum bark daphne mezereum bark gelsemium sempervirens root gelsemium sempervirens root
Indications and Usage:
Use for temporary relief of pain, itch, and minor skin irritation.
Warnings:
Warnings for external use only. avoid contact with eyes. stop use and ask a doctor if symptoms persist for more than 7 days or worsen. keep out of reach of children. if swallowed, get medical help or contact a poison control center right away.
Dosage and Administration:
Directions apply generously to affected areas up to 4 times a day
Stop Use:
Stop use and ask a doctor if symptoms persist for more than 7 days or worsen.
Package Label Principal Display Panel:
Package labeling: outer package inner package